Originally used to treat diabetes, it is now used off-label or longevity. Traditional doctors require high A1C or onset of diabetes. AgelessRx prescribes it for the longevity use-case. Prescription-strength, reviewed by licensed US prescriber, free medical evaluation provided.
May be an affiliate link, see footer.
Metformin has strong RCT evidence for glycemic control in type 2 diabetes and observational data suggesting cardiovascular and mortality benefits in diabetic populations. The TAME trial (Targeting Aging with Metformin) is ongoing in non-diabetic older adults to test longevity claims, but results are not yet published. Current evidence supports use in diabetes; longevity benefits in healthy people remain mechanistic.
Metformin activates AMP-activated protein kinase (AMPK), a cellular energy sensor that regulates glucose metabolism and mitochondrial function. It reduces hepatic glucose production and improves insulin sensitivity, lowering blood glucose levels. In aging research, AMPK activation is hypothesized to extend healthspan by improving metabolic efficiency and reducing inflammation.
Randomized trial
“IMPORTANCE: The effects of tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, as an addition to insulin glargine for treatment of type 2 diabetes have not been described.”
“IMPORTANCE: An intermittent fasting plan consisting of 2 nonconsecutive fasting days and 5 days of habitual intake per week and meal replacement diet (5:2 MR) could provide additional benefits to patients with type 2 diabetes.”
“AIM OF THE STUDY: Metformin is recommended as the first-line treatment of type 2 diabetes mellitus.”
“BACKGROUND: Metformin is the first-line treatment for diabetes, with multiple long-term benefits.”
Metformin is FDA-approved for type 2 diabetes, not as a longevity supplement in non-diabetic populations. The TAME trial, expected to report around 2024–2025, will be the first large RCT of metformin in aging; until then, longevity claims rest on mechanism and observational data in diabetics, not prospective trials in healthy older adults. Rare risk of lactic acidosis in renal impairment. Long-term safety and optimal dosing in non-diabetic aging remain unknown.
EOD publishes opinions and summaries of research about supplements, services, and protocols. It is not medical advice. Consult a qualified healthcare provider before changing your supplement, exercise, sleep, or medication regimen.
Some outbound links on EOD are affiliate links. If you buy through them we may earn a small commission, at no extra cost to you. It never influences what we publish or how it's ranked. Full disclosure.
EOD · 123 Placeholder Street, New York, NY 10001